Edition:
India

Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

28.54CAD
18 May 2018
Change (% chg)

$0.49 (+1.75%)
Prev Close
$28.05
Open
$28.29
Day's High
$28.69
Day's Low
$28.29
Volume
923,168
Avg. Vol
1,440,180
52-wk High
$30.56
52-wk Low
$14.01

Latest Key Developments (Source: Significant Developments)

Valeant Announces Pricing Of Private Offering Of Notes
Friday, 18 May 2018 

Valeant Pharmaceuticals International Inc ::VALEANT ANNOUNCES PRICING OF PRIVATE OFFERING OF NOTES.VALEANT - UNIT PRICED PREVIOUSLY ANNOUNCED OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 8.50% UNSECURED SENIOR NOTES DUE 2027.  Full Article

Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement
Saturday, 12 May 2018 

May 11 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT.PROGENICS PHARMA- CO,OTHER PLAINTIFFS ALLEGE PRODUCTS FOR WHICH PAR IS SEEKING U.S. MARKETING APPROVAL INFRINGES CO'S,OTHER PLAINTIFFS' U.S. PATENTS.  Full Article

Valeant Will Become Bausch Health Companies Inc
Tuesday, 8 May 2018 

May 8 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT WILL BECOME BAUSCH HEALTH COMPANIES INC..VALEANT - AS PART OF NAME CHANGE, WILL ROLL OUT A NEW CORPORATE BRAND IDENTITY IN JULY 2018.VALEANT - NEW CORPORATE BRAND IDENTITY WILL INCLUDE NEW IMAGERY AND WEB SITE, AND WILL TRADE UNDER A NEW SYMBOL, BHC.  Full Article

Salix Receives FDA Approval For Plenvu, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
Monday, 7 May 2018 

May 7 (Reuters) - Valeant Pharmaceuticals International Inc ::SALIX RECEIVES FDA APPROVAL FOR PLENVU®, NEXT GENERATION 1-LITER BOWEL CLEANSING PREPARATION FOR COLONOSCOPIES.SALIX RECEIVES FDA APPROVAL FOR PLENVU®, NEXT GENERATION 1-LITER BOWEL CLEANSING PREPARATION FOR COLONOSCOPIES.  Full Article

Bausch + Lomb Says FDA Approved Ultra Family Of Contact Lenses For Extended Wear
Wednesday, 2 May 2018 

May 2 (Reuters) - Valeant Pharmaceuticals International Inc ::BAUSCH + LOMB ULTRA® CONTACT LENSES RECEIVE FDA APPROVAL FOR EXTENDED WEAR INDICATION.BAUSCH + LOMB SAYS U.S. FDA APPROVED BAUSCH + LOMB ULTRA FAMILY OF CONTACT LENSES FOR EXTENDED WEAR OF UP TO 6 NIGHTS & 7 DAYS OF CONTINUOUS WEAR.  Full Article

Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
Friday, 13 Apr 2018 

April 12 (Reuters) - Valeant ::ARBITRAL TRIBUNAL DECIDES IN FAVOR OF VALEANT IN UCERIS ARBITRATION.TRIBUNAL ISSUED A RULING REJECTING COSMO'S CLAIMS IN THEIR ENTIRETY RELATED TO UCERIS ARBITRATION.ARBITRAL TRIBUNAL ORDERED COSMO TO PAY ENTIRETY OF VALEANT'S LEGAL COSTS OF ABOUT $3.1 MILLION.  Full Article

Valeant Canada Announces Health Canada Approval Of Contrave Extended
Monday, 26 Mar 2018 

March 26 (Reuters) - Valeant Canada: :VALEANT CANADA ANNOUNCES HEALTH CANADA APPROVAL OF CONTRAVE EXTENDED-RELEASE TABLETS FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS.  Full Article

Valeant Announces Pricing Of Private Offering Of Senior Notes
Tuesday, 13 Mar 2018 

March 12 (Reuters) - Valeant ::ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR NOTES.‍COMPANY'S WHOLLY OWNED INDIRECT SUBSIDIARY, HAS PRICED ITS PREVIOUSLY ANNOUNCED OFFERING OF 9.250% SENIOR NOTES DUE 2026​.‍AGGREGATE SIZE OF OFFERING REFLECTS INCREASE OF $250 MILLION FROM PREVIOUSLY ANNOUNCED OFFERING SIZE OF $1.25 BILLION TO $1.5 BILLION.‍NOTES WERE OFFERED AT PAR​.  Full Article

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Valeant Pharmaceuticals International Inc ::ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-121 ACNE TREATMENT IN LOTION FORM.ORTHO DERMATOLOGICS - PDUFA ACTION DATE IS AUG. 27, 2018.  Full Article

Valeant Pays Down $300 Million Of Senior Secured Term Loans
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT PAYS DOWN $300 MILLION OF SENIOR SECURED TERM LOANS.VALEANT - AS OF DEC. 31, 2017, COMPANY'S TOTAL DEBT IS APPROXIMATELY $25.7 BILLION.VALEANT - IN AGGREGATE, VALEANT HAS NOW REDUCED ITS DEBT BY MORE THAN $6.5 BILLION SINCE END OF Q1 OF 2016.  Full Article

UPDATE 2-Ex-Valeant, Philidor executives convicted of kickback scheme

NEW YORK, May 22 A former Valeant Pharmaceuticals International Inc executive and the former chief of mail order pharmacy Philidor Rx Services were found guilty on Tuesday of defrauding Valeant through a multimillion-dollar kickback scheme.